Integra LifeSciences has completed the acquisition of TEI Biosciences and TEI Medical, for around $312m, allowing the firm to expand its reconstructive surgery and regenerative wound care product offerings.
The deal was first announced in June this year.
Integra president and CEO Peter Arduini said: "We are enthusiastic about the strategic fit of these two organizations, and the positive impact TEI has on both top and bottom-line metrics.
"With this acquisition, we have a significant opportunity to build our platform and fuel a robust pipeline of regenerative products to accelerate Integra’s overall growth."
Based in Waltham of Massachusetts, TEI Biosciences is a biomedical firm that produces SurgiMend that can be used for a wide range of soft tissue repair and regeneration applications ranging from dura and hernia repair to plastic and reconstructive surgery.
TEI Medical is a spin-off from TEI Biosciences that holds exclusive license to the TEI regenerative technology in the fields of wound healing and orthopedics.
It sells PriMatrix and PriMatrix Ag directly in the US and through international partners in other countries.
Integra is involved in providing regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies.